Introduction {#s001}
============

T[he core motor features]{.smallcaps} of Parkinson\'s disease are associated with a loss of dopaminergic neurons in the substantia nigra pars compacta and their projection to the posterior striatum where dopamine is released.^[@B1],[@B2]^ Current Parkinson\'s disease treatments focus on the acute restoration of dopaminergic activity in the striatum through daily oral administration of the dopamine precursor L-Dopa, and/or dopaminergic agonists.^[@B3]^ Although such treatments provide good control of many of the motor features in the initial stages of the disease, L-Dopa therapy becomes less reliable with disease progression as a range of motor and non-motor complications emerge, such as on--off phenomena, peak-dose dyskinesias, and a range of neuropsychiatric and cognitive problems.^[@B4],[@B5]^ A therapeutic approach that restores long-term continuous dopaminergic function, restricted to the dopamine-depleted striatum, may provide an effective and durable treatment while minimizing off-target effects.^[@B6]^

Gene therapy approaches for Parkinson\'s disease using adeno-associated virus vectors have been shown to be well tolerated in early-phase clinical trials of mid- to late-stage patients.^[@B7]^ The therapeutic rationale for these studies was based on: (i) neuroprotection of nigral dopaminergic neurons and their projections through delivery of genes encoding a neurotrophic factor,^[@B10],[@B13]^ (ii) enhanced conversion of L-Dopa to dopamine by gene transfer of the enzyme aromatic amino acid decarboxylase (AADC),^[@B7]^ or (iii) modulation of basal ganglia outputs by delivery of glutamic acid decarboxylase (GAD) to the subthalamic nucleus.^[@B11],[@B12]^ Although Phase I studies reported encouraging efficacy data, follow-up studies showed no or modest difference in motor improvements compared to placebo-control patients.^[@B12],[@B13]^

The 1 year results were previously reported of the open-label part of a Phase I/II clinical trial evaluating the safety and efficacy of ProSavin---an equine infectious anemia virus (EIAV)-based gene therapy approach aimed at local and continuous dopamine replacement to the motor striatum of Parkinson\'s disease patients.^[@B14]^ The ProSavin vector encodes the three dopamine biosynthetic enzymes---tyrosine hydroxylase (TH), AADC, and GTP-cyclohydrolase 1 (CH1)---and has been shown to convert transduced non-dopaminergic striatal neurons into dopamine-producing cells.^[@B15]^

This clinical study showed that ProSavin was well tolerated, with promising indications of efficacy.^[@B14]^ Here, the long-term follow-up of these patients is reported, including assessments of safety and efficacy in 13 patients up to at least 5 years, and in some cases to 8 years, post treatment with ProSavin.

Methods {#s002}
=======

Study design {#s003}
------------

A detailed description of the Phase I/II study has been previously published.^[@B14]^ All patients were subsequently enrolled into this open-label follow-up study to investigate the long-term safety and efficacy of ProSavin for up to 10 years post treatment. The study protocols were approved by the ethics committee of each participating institution and complied with the Declaration of Helsinki, current Good Clinical Practice guidelines, and local laws and regulations. The Phase I/II study and ongoing open-label follow-up are registered with the [ClinicalTrials.gov](ClinicalTrials.gov) registry (NTC00627588 and NCT01856439; EudraCT numbers: 2007-001109-26 and 2009-017253-35).

Participants {#s004}
------------

As previously described, 15 patients with idiopathic Parkinson\'s disease, as defined by the diagnostic criteria from the core assessment program for surgical interventional therapies (CAPSIT \[1999\]), received ProSavin in one of four dose cohorts.^[@B14]^ Entry criteria included: age between 48 and 65 years, disease duration of at least 5 years, Hoehn and Yahr stage 3 or 4 in the off state, Unified Parkinson\'s Disease Rating Scale (UPDRS) part III (off) scores between 20 and 60, motor complications associated with L-Dopa therapy, a stable medication regimen for at least 4 weeks prior to surgery, and ≥50% improvement in the UPDRS part III score between the off and on states in response to an acute L-Dopa challenge ([Table 1](#T1){ref-type="table"}).

###### 

Baseline demographic data

  *Patients*   *Cohort*   *Age (years)*   *Disease duration (years)*   *UPDRS motor score, off/on*   *Total UPDRS score, off/on*   *L-Dopa equivalent dose*
  ------------ ---------- --------------- ---------------------------- ----------------------------- ----------------------------- --------------------------
  L1           1          62              8                            23/6                          49/19                         2,547
  L2           1          57              8                            30/8                          61/24                         1,329
  L3           1          58              16                           28/11                         70/35                         1,998
  M4           2a         57              17                           29/8                          63/20                         2,164
  M5           2a         56              12                           30/14                         58/24                         1,572
  M6           2a         49              9                            34/7                          74/23                         2,523
  M7           2b         64              9                            49/19                         83/31                         1,785
  M8           2b         59              13                           38/15                         67/31                         1,088
  M9           2b         57              15                           46/9                          68/20                         1,775
  H10          3          48              22                           37/8                          59/21                         1,535
  H11          3          58              10                           35/10                         71/27                         1,844
  H12          3          61              26                           52/13                         91/25                         1,180
  H13          3          63              16                           49/23                         90/52                         1,691
  H14          3          57              19                           52/23                         94/47                         699
  H15          3          55              9                            44/18                         71/30                         1,593
  *Mean*       NA         57.4            13.9                         38/13                         71/29                         1,688
  *SD*         NA         4.47            5.47                         9.61/5.70                     13.17/9.74                    505.03

Patients are listed in the order in which they received treatment.

UPDRS, Unified Parkinson\'s Disease Rating Scale; L, low (1.9 × 10^7^ TU); M, mid (4.0 × 10^7^ TU); H, high dose (1 × 10^8^ TU); Off, off-medication state; On, on-medication state.

Procedure {#s005}
---------

All patients received ProSavin via bilateral injections into the striatum under general anesthesia. Three dose levels of ProSavin were assessed in four patient cohorts. Three patients were included at dose level 1 (low dose, 2 × 10^7^ transducing units \[TU\]; cohort 1), six patients at dose level 2 (mid dose, 4 × 10^7^ TU; cohorts 2a and 2b), and six patients at dose level 3 (high dose, 1 × 10^8^ TU; cohort 3). A modified delivery method of administration was introduced for cohorts 2b and 3 to increase the rate of delivery and enhance the distribution of the vector. The modified delivery method included a change from 1 to 3 μL/min, with a reduction of diameter of the cannula from 25 to 28 gauge and from five needle tracks (each with five depots each) to three needle tracks (each with one depot; see [Supplementary Data](#SD1){ref-type="supplementary-material"}; Supplementary Data are available online at [www.liebertpub.com/humc](www.liebertpub.com/humc)).

Outcomes {#s006}
--------

The primary endpoints of the Phase I/II study were the number and severity of adverse events (AEs) associated with ProSavin administration and motor responses as assessed using the UPDRS part III in the defined off state 6 months post vector administration. The UPDRS is a widely used assessment tool used in patients with Parkinson\'s disease. It is made up of six different sections. Part I evaluates mentation, behavior, and mood. Part II evaluates activities of daily life (ADLs), including speech, swallowing, handwriting, dressing, hygiene, falling, levels of salivation, turning in bed, walking, and cutting food. Part III is a clinician-scored itemized motor evaluation. Part IV evaluates the complications of dopaminergic therapy. Part V gives a Hoehn and Yahr staging of the severity of the Parkinson\'s disease. Part VI contains the Schwab and England ADL scale. Patients were thereafter evaluated at least every 6 months for 3 years and thereafter on an annual basis (which will be up to 10 years in the open-label follow-up). AEs were assessed at every visit, and all events were recorded, including those that were reported spontaneously or on general questioning and those observed directly by the investigators. Efficacy assessments, including the UPDRS parts I, II, and III (in the off and on states) and UPDRS part IV, were done at least every 6 months up to 3 years and yearly thereafter up to year 6, with a final assessment planned at year 10. Eight patients have received deep brain stimulation (DBS) at different time points post ProSavin injections, and subsequent assessments for these patients were not included in the UPDRS analysis. UPDRS off assessments were performed in the practically defined off state following overnight drug withdrawal. UPDRS on assessments were performed 1 h after a dose of L-Dopa that was tailored for each patient at baseline, with the same dose being used at each subsequent assessment. Individual doses of dopaminergic medication were kept constant throughout follow-up, unless alterations were required in response to AEs. Doses were assessed at every visit and expressed as L-Dopa equivalent daily dose (LEDD). Quality of life (using the Parkinson\'s Disease Questionnaire \[PDQ-39\]) was assessed at least every 6 months up to 3 years and yearly thereafter.

Statistical analysis {#s007}
--------------------

The UPDRS and PDQ-39 scores were analyzed by a Wilcoxon paired test at 24 months. Data management and statistical summaries were performed by Quanticate (UK) Ltd. (Hitchin, United Kingdom). Verbatim AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA).

Results {#s008}
=======

Patients {#s009}
--------

All baseline patient characteristics have been previously described. With the exception of one patient (H14) who declined assessment of efficacy after the 12-month assessment (but continued safety assessments), all patients were assessed for efficacy for at least 2 years of follow-up ([Fig. 1](#f1){ref-type="fig"}).

![Trial profile. Box 1 represents cohort 1: *n* = 3 patients included at dose level 1 (low dose, 1.9 × 10^7^ transducing units \[TU\]; 8 years of follow-up), which involved four needle tracks of five ProSavin deposits per track in each motor putamen. Box 2 represents cohort 2: *n* = 3 patients at dose level 2 (mid dose, 4.0 × 10^7^ TU; 7 years of follow-up), which involved five needle tracks of five ProSavin deposits in each track placed within the motor putamen. Box 3 represents cohort 2b: *n* = 3 patients at dose level 2 (mid dose, 4.0 × 10^7^ TU; 6 years of follow-up), with the new delivery method leading to three needle tracks with one deposit per track in each motor putamen. Box 4 represents cohort 3: *n* = 6 patients at dose level 3 (high dose, 1 × 10^8^ TU; 5 years of follow-up), with the new delivery method of three needle tracks, one deposit per track, in each motor putamen. A modified delivery method of administration was introduced for cohorts 2b and 3 to increase the rate of delivery from 1 to 3 μL/min and a reduction of diameter of the cannula from 25 to 28 gauge.](fig-1){#f1}

Eight patients in total received bilateral DBS of the subthalamic nucleus after the 2- (M7, M8, H11), 3- (H14), 4- (H12), 5- (M4, H10), or 6-year (M6) assessment battery. Post-DBS assessments were not included in this analysis except for overall safety.

Safety {#s010}
------

Across all time points of follow-up, treatment-emergent AEs were reported in every patient, with the majority (575/671) considered to be unrelated to ProSavin ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}, [S2](#SD3){ref-type="supplementary-material"}, [S3](#SD4){ref-type="supplementary-material"}). Thirty serious AEs were reported across 12 patients, and all were considered unrelated or unlikely to be related to the study drug and the surgical procedure. Two deaths were reported: L1 after their year 6 assessment (peritonitis), and M7 after year 4 (cardio-respiratory arrest), with neither death considered related to ProSavin treatment or to their underlying Parkinson\'s disease.

There were 96 drug-related AEs reported post treatment ([Table 2](#T2){ref-type="table"}), and the majority of these (*n* = 87; 91%) were mild and/or occurred in the first year of follow-up (*n* = 57; 61%). The most common ProSavin-related AEs, in both the first year post treatment and follow-up thereafter, were increased dyskinesias (33 AEs in 11 patients; 30 mild, 2 moderate, 1 severe) and on--off phenomena (22 AEs in 11 patients; all mild). Increased dyskinesias generally resolved with a reduction in the patients\' oral dopaminergic medication. The safety profile was similar across all dose cohorts.

###### 

All drug-related adverse events

                                                      *Number of events*                      
  --------------------------------------------------- -------------------- ----- ----- ------ ------
  *Total number of adverse events*                    87                   6     3     96     15
  *Nervous system disorders*                          *64*                 *3*   *1*   *68*   *15*
  Dyskinesia                                          30                   2     1     33     11
  On and off phenomenon                               22                   0     0     22     11
  Headache                                            4                    0     0     4      3
  Akinesia                                            3                    0     0     3      3
  Balance disorder                                    1                    0     0     1      1
  Brain edema^[a](#tf3){ref-type="table-fn"}^         1                    0     0     1      1
  Dysarthria                                          1                    0     0     1      1
  Speech disorder                                     1                    0     0     1      1
  Tremor                                              0                    1     0     1      1
  *Psychiatric disorders*                             *9*                  *1*   *1*   *11*   *7*
  Delusional perception                               3                    0     0     3      3
  Anxiety                                             1                    1     0     2      2
  Hallucination                                       2                    0     0     2      2
  Abnormal dreams                                     1                    0     0     1      1
  Acute psychosis                                     0                    0     1     1      1
  Confused state                                      1                    0     0     1      1
  Hallucination, visual                               1                    0     0     1      1
  *Investigations*                                    *7*                  *0*   *0*   *7*    *5*
  Nuclear magnetic resonance imaging brain abnormal   3                    0     0     3      3
  Nuclear magnetic resonance imaging abnormal         2                    0     0     2      2
  Weight decreased                                    1                    0     0     1      1
  Weight increased                                    1                    0     0     1      1
  *Musculoskeletal and connective tissue disorders*   *4*                  *0*   *0*   *4*    *4*
  Back pain                                           1                    0     0     1      1
  Musculoskeletal pain                                1                    0     0     1      1
  Myalgia                                             1                    0     0     1      1
  Neck pain                                           1                    0     0     1      1
  *Injury, poisoning, and procedural complications*   *2*                  *0*   *0*   *2*    *2*
  Fall                                                1                    0     0     1      1
  Subdural hematoma^[b](#tf4){ref-type="table-fn"}^   1                    0     0     1      1
  *Blood and lymphatic system disorders*              *0*                  *1*   *0*   *1*    *1*
  Anemia                                              0                    1     0     1      1
  *Gastrointestinal disorders*                        *1*                  *0*   *0*   *1*    *1*
  Nausea                                              1                    0     0     1      1
  *Renal and urinary disorders*                       *0*                  *1*   *0*   *1*    *1*
  Glomerulonephritis                                  0                    1     0     1      1

Along the injection site only.

Bleeding under burr hole.

The only immune responses seen were in cohort 3 where low-level antibody responses against the VSV-G envelope protein were detected in four of the six patients, and in three of these four patients, antibodies to p26 protein (part of the gag protein that makes up the viral particle) were observed.^[@B14]^

Efficacy {#s011}
--------

Similar to the previously reported data for the 6- and 12-month assessments, a significant reduction in mean UPDRS part III (off) motor scores compared to baseline scores was observed across the 14 patients evaluated after 2 years of follow-up ([Table 3](#T3){ref-type="table"}; 29.2 vs. 37.4, *p* \< 0.05). Of the 14 patients, 10 showed sustained improvements from baseline at this time point. No statistically significant difference was seen between the differently dosed cohorts. Although four patients who received DBS were withdrawn from the efficacy analysis at follow-up after the 2- or 3-year assessments, 10/11 patients and 8/10 patients continued to demonstrate an improvement in UPDRS III (off) scores relative to baseline at the 3- or 4-year follow-up, respectively. The magnitude of improvement in these patients was generally similar to the effects observed at the 12- and 24-month time points. Of the patients who reached the 5- or 6-year follow-up, six out of nine patients and four out of six patients continued to have improved UPDRS III (off) scores relative to their baseline, which would also be consistent with the fact that they did not require further intervention with DBS.

###### 

UPDRS part III scores in on and off states for each patient, by time point---post DBS data excluded

  *Patients*                                            *Baseline*   *6 months*   *12 months*   *24 months*   *36 months*   *48 months*   *60 months*   *72 months*
  ----------------------------------------------------- ------------ ------------ ------------- ------------- ------------- ------------- ------------- -------------
  *UPDRS part III off score (% change from baseline)*                                                                                                   
  L1                                                    23           12 (−48%)    13 (−43%)     16 (−30%)     20 (−13%)     19 (−17%)     29 (26%)      28 (22%)
  L2                                                    30           26 (−13%)    27 (−10%)     30 (0%)       35 (17%)      32 (7%)       31 (3%)       26 (−13%)
  L3                                                    28           20 (−29%)    19 (−32%)     20 (−29%)     21 (−25%)     22 (−21%)     26 (−7%)      27 (−4%)
  M4                                                    29           21 (−28%)    24 (−17%)     30 (3%)       26 (−10%)     27 (−7%)      34 (17%)      NA
  M5                                                    30           24 (−20%)    26 (−13%)     19 (−37%)     24 (−20%)     24 (−20%)     29 (−3%)      29 (−3%)
  M6                                                    34           16 (−53%)    15 (−56%)     18 (−47%)     16 (−53%)     15 (−56%)     15 (−56%)     24 (−29%)
  M7                                                    49           34 (−31%)    39 (−20%)     44 (−10%)     NA            NA            NA            NA
  M8                                                    38           24 (−37%)    32 (−16%)     39 (3%)       NA            NA            NA            NA
  M9                                                    46           18 (−61%)    24 (−48%)     22 (−52%)     28 (−39%)     26 (−43%)     35 (−24%)     46 (0%)
  H10                                                   37           26 (−30%)    17 (−54%)     21 (−43%)     28 (−24%)     NA            19 (−49%)     NA
  H11                                                   35           24 (−31%)    27 (−23%)     39 (11%)      NA            NA            NA            NA
  H12                                                   52           46 (−12%)    39 (−25%)     46 (−12%)     41 (−21%)     28 (−46%)     NA            NA
  H13                                                   49           29 (−41%)    33 (−33%)     30 (−39%)     31 (−37%)     37 (−24%)     45 (−8%)      NA
  H14                                                   52           33 (−37%)    38 (−27%)     NA            NA            NA            NA            NA
  H15                                                   44           32 (−27%)    26 (−41%)     35 (−20%)     31 (−30%)     47 (7%)       NA            NA
  *UPDRS part III on score (% change from baseline)*                                                                                                    
  L1                                                    6            7 (17%)      6 (0%)        7 (17%)       14 (133%)     10 (67%)      21 (250%)     24 (300%)
  L2                                                    8            10 (25%)     11 (38%)      11 (38%)      19 (138%)     19 (138%)     18 (125%)     21 (163%)
  L3                                                    11           7 (−36%)     7 (−36%)      10 (−9%)      15 (36%)      12 (9%)       19 (73%)      21 (91%)
  M4                                                    8            7 (−13%)     8 (0%)        10 (25%)      10 (25%)      9 (13%)       10 (25%)      NA
  M5                                                    14           14 (0%)      14 (0%)       13 (−7%)      16 (14%)      15 (7%)       17 (21%)      20 (43%)
  M6                                                    7            7 (0%)       6 (−14%)      9 (29%)       7 (0%)        6 (−14%)      6 (−14%)      5 (−29%)
  M7                                                    19           15 (−21%)    15 (−21%)     17 (−11%)     NA            NA            NA            NA
  M8                                                    15           13 (−13%)    15 (0%)       12 (−20%)     NA            NA            NA            NA
  M9                                                    9            5 (−44%)     5 (−44%)      8 (−11%)      12 (33%)      11 (22%)      14 (56%)      10 (11%)
  H10                                                   8            8 (0%)       8 (0%)        9 (13%)       8 (0%)        NA            8 (0%)        NA
  H11                                                   10           8 (−20%)     9 (−10%)      11 (10%)      NA            NA            NA            NA
  H12                                                   13           11 (−15%)    9 (−31%)      15 (15%)      12 (−8%)      12 (−8%)      NA            NA
  H13                                                   23           16 (−30%)    21 (−9%)      25 (9%)       14 (−39%)     20 (−13%)     19 (−17%)     NA
  H14                                                   23           24 (4%)      33 (43%)      NA            NA            NA            NA            NA
  H15                                                   18           20 (11%)     15 (−17%)     13 (−28%)     10 (−44%)     10 (−44%)     NA            NA

No significant improvements in UPDRS part III (on) motor scores, compared to baseline, were observed for up to 2 years of follow-up ([Table 3](#T3){ref-type="table"}). All patients in the low-dose cohort, and three of the five mid-dose patients who could be evaluated, showed worsening UPDRS part III (on) scores compared to baseline at the 3-year follow-up. However, in the high-dose cohort, all of the patients who were evaluated from 3 years onwards showed equivalent or improved scores relative to baseline at every time point.

The previously reported significant reduction in mean total UPDRS (off) scores compared to baseline scores at 1 year was maintained at the 2-year follow-up time point in the 14 evaluable patients ([Table 3](#T3){ref-type="table"}; 69**·**6 vs. 58**·**3, p \< 0.05).^[@B14]^ No significant improvement in mean total UPDRS (on) scores at 2 years versus baseline was observed (24.4 vs. 27.3; *p* = n.s.), and there were no sustained improvements observed in the majority of patients at longer follow-up times ([Table 4](#T4){ref-type="table"}).

###### 

Total UPDRS scores in on and off states for each patient, by time point---post DBS data excluded

  *Patients*                *Baseline*   *6 months*   *12 months*   *24 months*   *36 months*   *48 months*   *60 months*   *72 months*
  ------------------------- ------------ ------------ ------------- ------------- ------------- ------------- ------------- -------------
  *Total UPDRS off score*                                                                                                   
  L1                        49           30           30            37            44            43            67            62
  L2                        61           45           59            62            73            65            70            61
  L3                        70           41           43            38            42            49            61            65
  M4                        63           50           52            69            59            59            65            NA
  M5                        58           54           53            30            47            40            60            54
  M6                        74           54           44            58            53            49            53            60
  M7                        83           67           69            84            NA            NA            NA            NA
  M8                        67           46           58            67            NA            NA            NA            NA
  M9                        68           44           54            51            56            58            71            89
  H10                       59           54           49            51            66            NA            57            NA
  H11                       71           58           65            79            NA            NA            NA            NA
  H12                       91           84           73            86            82            71            NA            NA
  H13                       90           47           53            49            57            50            74            NA
  H14                       94           63           64            NA            NA            NA            NA            NA
  H15                       71           44           39            55            53            71            NA            NA
  *Total UPDRS on score*                                                                                                    
  L1                        19           13           14            15            23            22            48            48
  L2                        24           19           28            26            38            42            38            45
  L3                        35           15           18            17            22            27            39            49
  M4                        20           17           17            28            21            19            19            NA
  M5                        24           24           22            19            28            20            31            35
  M6                        23           25           22            26            25            17            31            22
  M7                        31           29           26            39            NA            NA            NA            NA
  M8                        31           27           29            22            NA            NA            NA            NA
  M9                        20           18           16            20            24            30            33            32
  H10                       21           18           21            20            22            NA            23            NA
  H11                       27           22           25            26            NA            NA            NA            NA
  H12                       25           24           21            29            34            33            NA            NA
  H13                       52           27           34            35            25            30            36            NA
  H14                       47           33           41            NA            NA            NA            NA            NA
  H15                       30           25           22            20            20            19            NA            NA

Analysis of the UPDRS I, II (on and off), and IV scores demonstrated no significant differences from baseline scores in the 14 patients evaluated at 2 years ([Supplementary Tables S4--S6](#SD5){ref-type="supplementary-material"}). However, the majority of patients who could be evaluated showed improved or sustained scores from baseline up to the 4-year assessment. In the smaller numbers of patients who were followed up beyond 4 years, responses were generally similar or less favorable than baseline. Analysis of PDQ-39 scores demonstrated similar scores to baseline at the 2-year follow-up ([Supplementary Table S7](#SD6){ref-type="supplementary-material"}; 32.5 vs 32.1, *p* = n.s.). At later time points, around half of patients assessed showed a gradual decline in scores.

In long-term follow-up, the majority of patients continued to require a lower LEDD compared to baseline. In total, 10/14 patients and 8/12 patients benefited from a reduction in LEDD compared to baseline at 2 and 3 years of follow-up, respectively ([Table 5](#T5){ref-type="table"}). Of the patients followed up for 4, 5, and 6 years, 5/11 patients, 5/10 patients, and 4/6 patients received a lower LEDD than baseline, respectively.

###### 

L-Dopa equivalent dose (LEDD)---post DBS data excluded

  *Patients*   *Baseline*   *6 months*   *12 months*   *24 months*   *36 months*   *48 months*   *60 months*   *72 months*
  ------------ ------------ ------------ ------------- ------------- ------------- ------------- ------------- -------------
  L1           2,547        2,257        2,382         2,507         2,507         3,102         986           1,461
  L2           1,329        1,319        1,103         1,019         1,582         1,582         1,530         1,680
  L3           1,998        1,448        750           1,149         1,282         999           875           1,575
  M4           2,164        2,164        1,025         1,229         1,487         2,015         2,414         NA
  M5           1,572        1,572        1,572         1,238         1,238         1,052         998           1,098
  M6           2,523        2,257        2,257         1,548         1,615         1,615         1,848         1,958
  M7           1,785        1,936        2,036         2,305         NA            NA            NA            NA
  M8           1,088        1,088        1,088         1,160         NA            NA            NA            NA
  M9           1,775        1,525        1,400         1,400         1,725         1,850         1,800         2,582
  H10          1,535        1,160        1,360         1,660         1,810         2,314         3,002         NA
  H11          1,844        1,549        1,615         2,148         NA            NA            NA            NA
  H12          1,180        1,030        1,130         1,055         1,165         2,253         NA            NA
  H13          1,691        1,391        1,391         1,391         1,391         1,125         1,125         NA
  H14          699          633          699           NA            699           NA            NA            NA
  H15          1,593        1,530        1,530         1,573         1,928         2,229         2,344         NA

Discussion {#s012}
==========

The results of a Phase I/II clinical trial were previously reported describing the first-in-human use of a lentiviral-based gene therapy vector. In this study, ProSavin, an EIAV-derived lentiviral vector, was shown to have a favorable safety profile and encouraging efficacy signals following injection into the motor striatum of 15 patients with Parkinson\'s disease.^[@B14]^

The data reported here describes follow-up, for up to 8 years, of patients from the Phase I/II study and provides important additional information on the long-term safety and potential efficacy of this therapeutic approach. The safety data are generally consistent with those previously reported,^[@B14]^ with no drug- or procedure-related serious AEs during follow-up. The majority of drug-related AEs were on-medication dyskinesias adequately managed by lowering their L-Dopa medication, and encouragingly, the majority of drug-related AEs occurred within the first 12 months after treatment.

Eight patients received treatment with DBS, as they developed worsening off periods alternating with L-Dopa dyskinesias as a result of disease progression. It should be noted that no safety issue was observed with lead implantation or high frequency stimulation of the subthalamic nucleus in any of these cases (S. Palfi, pers. commun.). There was a very similar safety profile before and after DBS (compare [Table 2](#T2){ref-type="table"} and [Supplementary Table S1](#SD2){ref-type="supplementary-material"}).

In terms of efficacy, the significant improvement in motor function previously reported up to 12 months was maintained at 2 years across the 14 patients that were assessed at this time point (with one patient withdrawing consent for off assessments after 12 months of follow-up). Although statistical analyses were not performed beyond this time point, as several patients were withdrawn from the efficacy part of the study by virtue of having had DBS, the majority of patients who remained in the open-label follow-up continued to show improvements in their UPDRS (III) off scores at all time points. These efficacy findings are consistent with the fact that the lentiviral vector genome is integrated into the host-cell genome and transgene expression is maintained long term,^[@B16]^ as has recently been shown following administration of an EIAV lentiviral vector into the retina.^[@B17]^ Nonetheless, Parkinson\'s disease is a progressive disease. So, it is encouraging that the data indicate that the levels of dopamine achieved through this gene therapy approach may be sufficient to sustain a positive motor behavioral effect for several years.

Considering only the patients who were evaluated at the longer-term follow-up time points, it is interesting to note that patients M6, M9, H12, and H13, who were diagnosed with Parkinson\'s disease between 9 and 26 years prior to ProSavin treatment,^[@B14]^ showed particularly encouraging improvements from baseline in their UPDRS III (off) scores, with changes of 12--24 points at the 4-year assessment. Patient M6 was also evaluated at 6 years, and continued to show an approximately 30% improvement in both UPDRS III on and off scores, with a sustained reduction in LEDD, and a 17-unit improvement in PDQ-39 scores from baseline.

Although these data provide strong evidence to support an efficacy benefit for ProSavin in Parkinson\'s disease patients, the overall magnitude of effects are within the range reported for placebo study arms, albeit over shorter time frames, in other clinical trials for PD using surgical interventions.^[@B8],[@B13]^ The duration of such placebo effects have not been well studied. However, given that the improvements in motor scores were sustained for 6 years in some patients and confined to their "off" state assessments, combined with the fact that Parkinson\'s disease is a progressive neurodegenerative disease with an expected three- to four-point increase in the UPDRS part III (off) motor score per year,^[@B18],[@B19]^ the likelihood that the findings reported are attributable to the study treatment is strong. Nonetheless, interpretation of these findings must still be viewed with caution until a larger comparator study has been undertaken with placebo treatments, especially given the extent of patient attrition over the follow-up period in this study. An attrition that is not unexpected, given that the study recruited patients at relatively advanced stages of disease.

Given the small sample populations, it is difficult to assess dose response. It was previously reported that there were indications of positive responses in patients receiving the highest dose of ProSavin. These patients had the most consistent LEDD reduction post intervention, the highest mean improvement in UPDRS III (off) motor scores at 1 year, and a significant change from baseline in ^[@B11]^C-raclopride binding potential.^[@B14]^ At 2 years of follow-up, a similar mean improvement from baseline in UPDRS III (off) scores was observed in the mid- and high-dose groups, which was higher than in the low-dose group. Again, interpretation of these observations must be made with caution due to the small patient numbers and the changes seen in the UPDRS III scores.

In conclusion, the new data demonstrate the long-term safety and promising efficacy profile of ProSavin in Parkinson\'s disease patients for up to 8 years of follow-up. These are the longest follow-up assessments reported in any Parkinson\'s disease gene therapy study. Although the results are encouraging, the data suggest that the optimal level of dopamine replacement may not have been achieved, since patients continued to require oral L-Dopa therapy to obtain maximal benefit, and some of the more severely affected patients required DBS 2--6 years following ProSavin administration. Further dose escalation using ProSavin would be challenging due to limitations on vector titers using current production processes and the volume of vector that can be safely administered into the human striatum. Therefore, a new vector (OXB-102) has been recently developed in which the configuration of three dopamine biosynthesis enzymes was further optimized to increase the capacity for dopamine production significantly compared to ProSavin.^[@B20]^ This vector is under preclinical development and, pending regulatory approval, will be assessed in a new Phase I/II study to determine the appropriate dose before a larger placebo-controlled Phase IIb clinical trial is undertaken.
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